A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
| Condition(s) | Solid Malignancies |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies. |
| Who can participate | Core Inclusion Criteria: * Histopathologically or cytologically confirmed diagnosis of malignant disease evaluable by RECIST v1.1 * Provision of signed written informed consent before any study-related activities, willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures and willing to permit access to stored historical tumor tissue, prior tumor radiological assessments and tumor biomarker data. * ECOG performance status of ≤ 2 with no deterioration over the previous 2 weeks. * Ability to take oral medications and be willing to record daily adherence to the study drug. * Women either of non-childbearing potential, either confirmed to be post-menopausal or of childbearing potential willing to practice effective contraception for the |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Carrick Therapeutics Limited |
| Locations | Dallas, Texas, United States; San Antonio, Texas, United States; Fairfax, Virginia, United States; Manchester, United Kingdom; Oxford, United Kingdom; Sutton, United Kingdom |
| Start date | 2024-08-16 |
| NCT ID | NCT06600789 |
| Official listing | https://clinicaltrials.gov/study/NCT06600789 |